1,041 material Form 8-K filings that 824 companies we cover made with the SEC in November 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Ross Stores said Executive Chairman Michael Balmuth will step down on January 31, 2026, and retire from the Board at that time. Independent director K. Gunnar Bjorklund, who has served on the Board since 2003 and as Lead Independent Director since 2023, will succeed him as Chairman on February 1, 2026. The filing describes this as a planned leadership succession and does not include any financial results or guidance.
Michael Balmuth remains Executive Chairman through January 31, 2026, then serves as Senior Advisor from February 1 through March 31, 2026
Balmuth will also retire from the Board when he steps down as Executive Chairman
K. Gunnar Bjorklund becomes Chairman of the Board effective February 1, 2026; he has been a director since 2003
The Company anticipates authorized Board seats will fall by one, to ten
Halozyme said Chief Financial Officer Nicole LaBrosse will stay in the role until the earliest of a new CFO's hiring, March 30, 2026, or an earlier date the company sets, and then leave for a new professional opportunity. Under a Transition and Release Agreement dated November 18, 2025, she is eligible for severance and equity and benefit treatment tied to a termination without cause, which shareholders can review in the company's 10-K for 2025.
CFO Nicole LaBrosse will serve until the earliest of a new CFO being hired, March 30, 2026, or an earlier date set by the company
Transition and Release Agreement dated November 18, 2025, conditioned on her compliance and a release of claims
Benefits include a 2025 annual bonus at 120% of target and severance equal to base salary, plus a pro-rated 2026 target bonus if she separates in 2026
Health coverage under COBRA paid by the company for one year after the separation date; full agreement to be filed with the 10-K for 2025
Stephen H. Rusckowski notified Tenet Healthcare on November 21, 2025 that he is resigning from the company's board of directors, effective immediately. The board reduced its size from thirteen to twelve directors in connection with the departure. The filing does not state a reason for the resignation or name a replacement.
Resignation notified to Tenet on November 21, 2025, effective immediately
Board size reduced from thirteen to twelve directors
Filing does not give a reason for the resignation or name a successor
Brixmor Property Group said CEO James M. Taylor Jr. will retire as CEO and as a board member effective January 1, 2026. The board appointed Brian T. Finnegan, the company's President and Chief Operating Officer and current interim CEO, to succeed him as permanent CEO and board member on the same date, under a new employment agreement that runs through December 31, 2028.
Taylor notified the company on November 19, 2025 that he will retire as CEO and from the board effective January 1, 2026.
The board appointed Finnegan, age 45, as CEO and a board member effective January 1, 2026; he will also keep the title of President.
Finnegan's new employment agreement sets a minimum base salary of $900,000 and a minimum target annual equity award of $3,000,000, starting with the 2026 grant.
Board Chair Sheryl M. Crosland said the appointment reflects execution of the CEO succession plan.
Neurocrine Biosciences amended the employment agreement with Eiry W. Roberts, M.D., its former Chief Medical Officer, on November 21, 2025. The amendment extends her employment term by 12 months, to December 31, 2026. Sanjay Keswani, M.D. has served as Chief Medical Officer since June 2, 2025, so the change does not alter that role.
Amendment dated November 21, 2025 extends the term of employment by an additional 12 months, expiring December 31, 2026.
Sanjay Keswani, M.D. succeeded Dr. Roberts as Chief Medical Officer effective June 2, 2025.
Under the prior agreement, Dr. Roberts served as Strategic Advisor through December 31, 2025.
Full text of the amendment is filed as Exhibit 10.1.
Kohl's Board appointed Michael J. Bender as Chief Executive Officer on November 23, 2025, effective that day, after he had served as interim CEO since May 1, 2025. The filing sets out his pay, including a $1,475,000 base salary and a long-term incentive target of no less than $9,500,000, which shareholders can review in the exhibits.
Appointment effective November 23, 2025; Bender had served as interim CEO since May 1, 2025
Annualized base salary of $1,475,000 with Annual Incentive Plan target of 175% of base salary
Annual long-term incentive target of no less than $9,500,000, with equity awards beginning spring 2026
Bender remains on the Board and its Finance Committee; Q3 earnings are due November 25, 2025
Prologis, Inc. announced that Damon Austin will become Chief Development Officer effective January 1, 2026. Austin, age 47, has been Managing Director and Global Head of Customer Led Development since January 1, 2023, and has been with the company since 2015.
Damon Austin named Chief Development Officer, effective January 1, 2026
Austin, age 47, currently serves as Managing Director, Global Head of Customer Led Development
Austin joined Prologis in 2015 and previously led Customer Led Development of the Americas (2021 to 2023) and Capital Deployment West Region (2018 to 2021)
Zebra Technologies said Chief People Officer Jeffrey Schmitz will step down on Dec. 31, 2025, and Vice President Melissa Luff Loizides will take the role on Jan. 1, 2026. Schmitz will remain as a Senior Vice President to lead integration of the Elo acquisition until he retires in the second quarter of 2026. The filing describes a planned leadership succession and does not report any change to financial results or guidance.
Jeffrey Schmitz steps down as Chief People Officer effective close of business Dec. 31, 2025
Melissa Luff Loizides becomes Chief People Officer on Jan. 1, 2026; she joined Zebra in 2014
Schmitz continues as Senior Vice President through his retirement in the second quarter of 2026, leading Elo integration
Labcorp's Board of Directors appointed Victor Bulto, President of Novartis U.S. and a member of the Novartis Executive Committee, as a director effective December 1, 2025. The filing describes the appointment as a board addition and includes no financial results, guidance, or changes to executive roles.
Board appointment made on November 20, 2025, effective December 1, 2025
Bulto has served as President of Novartis U.S. and on the Novartis Executive Committee since April 2022
Bulto will receive director compensation under Labcorp's director compensation program described in the April 4, 2025 proxy statement
RB Global disclosed that Chief Technology Officer Nancy King departed the company on November 20, 2025. Chief Operations Officer Steve Lewis will lead the technology organization and has taken over Ms. King's responsibilities on an interim basis.
Nancy King, Chief Technology Officer, departed on November 20, 2025
Steve Lewis, Chief Operations Officer, has assumed her responsibilities on an interim basis
The filing does not name a permanent successor or describe the reasons for the departure
Cracker Barrel director Gilbert Dávila resigned from the board effective immediately on November 20, 2025, and the board size was reduced from ten to nine members. The same day, shareholders approved an amendment to the 2020 Omnibus Incentive Plan at the annual meeting, and the inspector of election certified the final voting results on November 21, 2025. The filing does not give a reason for the resignation.
Gilbert Dávila resigned from the Board of Directors effective November 20, 2025; the filing gives no reason.
Board size reduced from ten to nine members.
Dávila was not among the nine directors elected: he received 6,716,130 for votes and 9,570,461 against.
Shareholders approved the 2020 Omnibus Incentive Plan amendment and say-on-pay (12,878,011 for, 3,325,141 against).
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.